Trametinib (CAS 871700-17-3) MEK Inhibitor Antitumor API

Trametinib (CAS 871700-17-3) is a high-purity MEK inhibitor antitumor API with a targeted signal pathway regulatory mechanism. It selectively inhibits the activity of MEK1 and MEK2 kinases, blocking the MAPK signaling cascade to suppress tumor cell proliferation, migration and angiogenesis, especially effective for tumors with BRAF mutations. Its refined crystalline form ensures consistent bioactivity and low impurity profiles, making it a reliable active ingredient for oncology pharmaceutical R&D.

Tailored for pharmaceutical manufacturers and precision oncology research institutions, this product adheres to strict international quality and regulatory standards. It addresses the core demand for targeted BRAF/MEK pathway raw materials, supporting the development of formulations for melanoma, non-small cell lung cancer and other solid tumor research. Its stable chemical structure guarantees extended shelf life, facilitating flexible formulation design for oral preparations and clinical trial applications.